Department of Medical Oncology, Hospital Clinico Universitario of Valencia, Biomedical Research Institute, INCLIVA, CIBERONC and University of Valencia, Valencia, Spain.
Department of Medical Oncology, Hospital Clinico Universitario of Valencia, Biomedical Research Institute, INCLIVA, CIBERONC and University of Valencia, Valencia, Spain.
ESMO Open. 2020 Oct;5(5):e000718. doi: 10.1136/esmoopen-2020-000718.
Aurora kinases (AURK) are key regulators of the mitotic spindle formation. AURK is frequently overexpressed in ovarian cancer and this overexpression has been frequently associated with prognosis in these tumours. Interestingly, AURK have been shown to interact with DNA repair mechanisms and other cell cycle regulators. These functions have brought light to Aurora family as a potential target for anticancer therapy. In the last years, two clinical trials with different AURK inhibitors have shown activity in epithelial and clear-cell ovarian cancer. Although there is a lack of predictive factors of AURK inhibition activity, recent trials have identified some candidates. This review will focus in the functions of the AURK family, its role as prognostic factor in epithelial ovarian cancer and potential clinical implications.
极光激酶（AURK）是有丝分裂纺锤体形成的关键调节因子。AURK 在卵巢癌中经常过表达，这种过表达与这些肿瘤的预后密切相关。有趣的是，AURK 已被证明与 DNA 修复机制和其他细胞周期调节剂相互作用。这些功能使 Aurora 家族成为癌症治疗的潜在靶点。在过去的几年中，两项不同的 Aurora 激酶抑制剂的临床试验已经显示在上皮性和透明细胞性卵巢癌中有活性。尽管缺乏 Aurora 激酶抑制活性的预测因素，但最近的试验已经确定了一些候选者。这篇综述将集中讨论 Aurora 家族的功能、在上皮性卵巢癌中的预后因素及其潜在的临床意义。
